JPMorgan Chase & Co. (NYSE: JPM) is slated to report its fourth-quarter 2019 earnings results on Tuesday, January 14, before the market opens. The bottom line will be benefited by lower costs and expenses while the net interest income and non-interest income growth could be driving the top line.
The net interest margins are expected to remain under the pressure from the lower interest rates. Investors are likely to keep an eye on credit conditions, general economic trends and their impact on debt repayments, as well as loan growth prospects.
The company’s results continued to be impacted by the global and US economies, financial markets activity, the geopolitical environment, the competitive environment, client and customer activity levels, and regulatory and legislative developments in the US and other countries where the Firm does business.
Analysts expect the company’s earnings to jump by 17.70% to $2.33 per share and revenue will rise by 3.80% to $27.82 billion for the fourth quarter. The company has surprised investors by beating analysts’ expectations thrice in the past fourth quarter. The majority of the analysts recommended a “hold” rating with an average price target of $133.77.
For the third quarter, JPMorgan posted an 8% increase in earnings helped by higher revenue. Net interest income rose by 2% driven by continued balance sheet growth and mix. The results were driven by strong client activity across products. The results were offset by weakening business sentiment and capital expenditures are mostly driven by increasingly complex geopolitical risks, including tensions in global trade.
For fiscal 2019, the company expects net interest income, on a managed basis, to be less than $57.5 billion, market dependent. Adjusted expenses are anticipated to be about $65.5 billion and net charge-offs are predicted to be about $5.5 billion.
JPMorgan’s competitor Wells Fargo (NYSE: WFC) is also scheduled to report its earnings results on the same day while Goldman Sachs (NYSE: GS) will report its results on Wednesday.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
